Treatment for myelosuppression
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CANTEX PHARMA
- Publication Date
- 2018-05-01
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
[0001] 1. Cross references to related applications
[0002] This application is based on 35 U.S.C. § 119(e) requiring U.S. provisional applications 61 / 724,836 (filed November 9, 2012); 61 / 702,207 (filed September 17, 2012); 61 / 678,053 (filed 2012 61 / 668,709 (filed 6 July 2012); 61 / 664,611 (filed 26 June 2012); 61 / 653,362 (filed 30 May 2012); 61 / 648,043 (filed May 16, 2012); 61 / 644,623 (filed May 9, 2012); and 61 / 644,556 (filed May 9, 2012), the entire contents of which are incorporated herein as refer to. 2. Background technology
[0003] Platelets play a key role in the coagulation mechanism. Thrombocytopenia below a certain level results in thrombocytopenia, which can be triggered by a range of clinical conditions or disorders and can extend from mild to life-threatening.
[0004] Thrombocytopenia can be triggered by diseases or conditions affecting the bone marrow, in which platelet precursors appear before entering the bloodstream; by diseases or conditions affecting ...